Amphastar Pharmaceuticals' (AMPH) "Neutral" Rating Reaffirmed at JPMorgan Chase & Co.

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report)'s stock had its "neutral" rating reissued by equities researchers at JPMorgan Chase & Co. in a report issued on Monday, MarketBeat reports. They currently have a $30.00 price objective on the stock, down from their previous price objective of $45.00. JPMorgan Chase & Co.'s price objective points to a potential upside of 20.68% from the company's current price.

A number of other research analysts have also weighed in on the company. Piper Sandler dropped their target price on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a report on Friday, March 21st. Wells Fargo & Company dropped their target price on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a report on Thursday, May 8th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $32.33.

Amphastar Pharmaceuticals Price Performance

Shares of Amphastar Pharmaceuticals stock traded up $0.54 on Monday, reaching $24.86. The company's stock had a trading volume of 510,253 shares, compared to its average volume of 477,506. The company has a market capitalization of $1.18 billion, a P/E ratio of 8.29, a PEG ratio of 2.19 and a beta of 0.78. Amphastar Pharmaceuticals has a 52-week low of $22.64 and a 52-week high of $53.96. The stock has a 50-day moving average price of $25.43 and a 200-day moving average price of $33.96. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82.

Insider Activity at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total transaction of $116,521.74. Following the completion of the transaction, the chief financial officer now owns 97,363 shares of the company's stock, valued at $2,681,377.02. This trade represents a 4.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last quarter, insiders sold 5,231 shares of company stock valued at $142,752. 27.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Barclays PLC boosted its stake in shares of Amphastar Pharmaceuticals by 53.3% in the third quarter. Barclays PLC now owns 74,456 shares of the company's stock valued at $3,613,000 after purchasing an additional 25,878 shares during the period. Arkadios Wealth Advisors boosted its stake in shares of Amphastar Pharmaceuticals by 5.2% in the fourth quarter. Arkadios Wealth Advisors now owns 27,964 shares of the company's stock valued at $1,038,000 after purchasing an additional 1,379 shares during the period. Dakota Wealth Management boosted its stake in shares of Amphastar Pharmaceuticals by 31.7% in the fourth quarter. Dakota Wealth Management now owns 5,486 shares of the company's stock valued at $204,000 after purchasing an additional 1,322 shares during the period. KBC Group NV boosted its stake in shares of Amphastar Pharmaceuticals by 43.1% in the fourth quarter. KBC Group NV now owns 2,159 shares of the company's stock valued at $80,000 after purchasing an additional 650 shares during the period. Finally, Pacer Advisors Inc. boosted its stake in shares of Amphastar Pharmaceuticals by 51,977.4% in the fourth quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company's stock valued at $50,139,000 after purchasing an additional 1,347,775 shares during the period. Hedge funds and other institutional investors own 65.09% of the company's stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.